Table 2:

Ibrutinib dosing and dose adjustments

	All patients	Age <65 years	del(17p13) present	RESONATE-2 published data
Initial dose < 420 mg	7.6%	2.5%	7.2%	0%
Requiring dose reduction to achieve stable dose without further adjustment	17.4%	13.1%	16.3%	Not reported
Requiring temporary dose interruption while on therapy	42%	35.9%	41.9%	Not reported
Median time of dose interruption	12 days	10 days	12 days	Not reported